Pilot Study of the Reprieve System to Treat Adults Hospitalized with Acute Decompensated Heart Failure

What this Trial Is About

Researchers are evaluating the Reprieve System to help manage fluid buildup in people with acute decompensated heart failure. This condition involves symptoms like difficulty breathing and swelling, and the study aims to see how well this device can assist in safely and quickly reducing excess fluid in hospitalized patients. The study is sponsored by Reprieve Cardiovascular, Inc and does not specify a clinical trial phase. Participants in the study will receive treatment with the Reprieve System, a hospital bedside device that automatically adjusts the infusion of an intravenous diuretic called furosemide and saline based on the patients urine output. The study includes different stages, with the first stage completed on 10 subjects and future stages planned to test varying water intake levels and new device features. Treatment will last up to 72 hours during hospitalization. During the study, participants will be closely monitored for how well the device functions over the treatment period. Researchers will track the personalized fluid management delivered by the system and assess the success of decongestion therapy. Participants must be hospitalized with heart failure symptoms and signs. The study involves catheter placement and requires adherence to study procedures. The total participation time depends on the hospital stay and treatment duration.

Reprieve System Pilot Study